.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma layer, taking up the top scientific research place at Sanofi.Quigley will start Sept. 30 as the French Big Pharma’s chief medical police officer as well as international head of study, Sanofi told Tough Biotech in an emailed declaration.Quigley is actually changing Frank Nestle, M.D., that left Sanofi this spring in the middle of a worldwide overhaul of the business’s R&D device. Nestle, who invested 8 years with the pharma, hopped over to Deerfield Control, where he currently works as a partner on the therapeutics staff as well as CEO of the organization’s healing exploration and development operations.
Quigley will definitely participate in Sanofi from a San Francisco-based biotech that remains in stealth, depending on to his LinkedIn profile. He’s currently detailed as the company’s founder, head of state and chief executive officer.Considering that August 2021, Quigley has served as an endeavor companion at SV Health Investors, a healthcare fund manager with existing assets in biotechs including BioAge, Cerevance, Dualitas Therapeutics as well as Nimbus Therapies, to name a few. Quigley in the past stored the best area at Dualitas, a biotech that continues to be in secrecy, depending on to STAT.The future Sanofi leader also formerly helmed Therini Biography, an immunotherapy biotech functioning to cultivate therapies for neurodegenerative ailments driven through general problems.Before investing the last couple of years in biotech, Quigley has an even longer record in Huge Pharma, most just recently acting as Gilead’s elderly vice president of investigation biology until the summertime of 2021.
Prior to that, he appeared greater than four years across a variety of management roles at Bristol Myers Squibb as well as functioned as a scientific supervisor at Johnson & Johnson’s Janssen arm prior to that.Sanofi claimed Quigley’s objective in his new role would be to “optimize our possibility of effectiveness through superior partnerships across our company as well as beyond, carrying best-in-class advancement as well as establishing and also sourcing brand new industry-leading talent with a commitment to diversity,” depending on to an inner memo obtained through STAT.